05.10.12
BASF today has acquired Equateq Ltd., a leading manufacturer of highly concentrated omega-3 fatty acids, for an undisclosed amount. With the acquisition, BASF extends its portfolio of omega-3 products for the pharmaceutical and dietary supplement industries with a new offering of highly concentrated omega-3 fatty acids.
Equateq’s proprietary chromatographic separation methods allow flexible formulation of omega-3 fatty acids at exceptional purity levels. “Equateq’s technologies will enable us to customize fatty acid concentrates with variable ratios of EPA (eicosapentaenoic acid) and
DHA (docosahexaenoic acid) at concentration levels of up to 99% purity. This is unique in the market,” explained Martin Widmann, senior vice president, Pharma Ingredients & Services at BASF.
Equateq has a production site located on the Isle of Lewis in Scotland with 47 employees. Equateq with all its employees will be integrated into the Pharma Ingredients & Services unit, which is part of BASF’s Nutrition & Health division. The integration is expected to be completed by the end of 2012.
Equateq’s proprietary chromatographic separation methods allow flexible formulation of omega-3 fatty acids at exceptional purity levels. “Equateq’s technologies will enable us to customize fatty acid concentrates with variable ratios of EPA (eicosapentaenoic acid) and
DHA (docosahexaenoic acid) at concentration levels of up to 99% purity. This is unique in the market,” explained Martin Widmann, senior vice president, Pharma Ingredients & Services at BASF.
Equateq has a production site located on the Isle of Lewis in Scotland with 47 employees. Equateq with all its employees will be integrated into the Pharma Ingredients & Services unit, which is part of BASF’s Nutrition & Health division. The integration is expected to be completed by the end of 2012.